Recruiting

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

Sponsor
Noom Inc. (Industry)
Enrollment
2,541 planned
Conditions
Obesity & Overweight; Weight Loss; Preventative Health; Body Weight; Cardiovascular Disease Risk Factor
Interventions
Noom Weight; Free Tier; Education-only control; Semaglutide; Tirzepatide; Microdose semaglutide; Microdose tirzepatide
Ages
adults
Registry
NCT07588984

Full record on ClinicalTrials.gov

From the registry

This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.

Primary outcomes

  • Change in Body Weight
  • Change in fasting glucose
  • Change in HbA1c
  • Change in LDL cholesterol

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered

In the news